{"id":"NCT02580058","sponsor":"Pfizer","briefTitle":"A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)","officialTitle":"A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-21","primaryCompletion":"2018-09-19","completion":"2022-07-12","firstPosted":"2015-10-20","resultsPosted":"2019-11-19","lastUpdate":"2023-07-10"},"enrollment":566,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ovarian Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"avelumab","otherNames":[]},{"type":"DRUG","name":"PLD","otherNames":["doxorubicin, caelyx"]}],"arms":[{"label":"avelumab","type":"EXPERIMENTAL"},{"label":"avelumab plus pegylated liposomal doxorubicin (PLD)","type":"EXPERIMENTAL"},{"label":"PLD","type":"ACTIVE_COMPARATOR"}],"summary":"A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization until the date of first documented progression or date of deaths from any cause, whichever came first, assessed up to 30 months (based on cutoff date: 19 September 2018).","effectByArm":[{"arm":"Avelumab","deltaMin":11.8,"sd":null},{"arm":"Avelumab + PLD","deltaMin":15.7,"sd":null},{"arm":"Pegylated Liposomal Doxorubicin (PLD)","deltaMin":13.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.8253"},{"comp":"OG001 vs OG002","p":"0.2082"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":295,"countries":["United States","Australia","Austria","Belgium","Canada","Czechia","Denmark","France","Greece","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Netherlands","Norway","Poland","Russia","Singapore","South Korea","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["37665777","37407274","34143970"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991009&StudyName=A%20Phase%203%2C%20Multicenter%2C%20Randomized%2C%20Open-label%20Study%20Of%20Avelumab%20%28msb0010718c%29%20Alone%20Or%20In%20Combination%20With%20Pegylated%20Liposomal%20Doxorubicin%20Versus%20Pegylated%20Liposomal%20Doxorubicin%20Alone%20In%20Patients%20With%20Platinum-resistant%2Frefractory%20Ovarian%20Cancer","https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991009&StudyName=A+Phase+3%2C+Multicenter%2C+Randomized%2C+Open-label+Study+Of+Avelumab+%28msb0010718c%29+Alone+Or+In+Combination+With+Pegylated+Liposomal+Doxorubicin+Versus+Pegylated+Liposomal+Doxorubicin+Alone+In+Patients+With+Platinum-resistant%2Frefractory+Ovarian+Cancer"]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":187},"commonTop":["Nausea","Fatigue","Abdominal pain","Anaemia","Vomiting"]}}